Zoetis (NYSE:ZTS) Now Covered by Barclays

Share on StockTwits

Barclays began coverage on shares of Zoetis (NYSE:ZTS) in a report issued on Tuesday morning, BenzingaRatingsTable reports. The firm issued an overweight rating and a $120.00 price objective on the stock.

ZTS has been the topic of a number of other reports. Stifel Nicolaus raised Zoetis from a hold rating to a buy rating and lifted their price objective for the company from $97.00 to $110.00 in a research report on Monday, March 4th. SunTrust Banks initiated coverage on Zoetis in a research report on Tuesday, March 19th. They set a hold rating and a $100.00 price objective on the stock. BMO Capital Markets lifted their price objective on Zoetis from $101.00 to $105.00 and gave the company a market perform rating in a research report on Thursday, May 9th. UBS Group initiated coverage on Zoetis in a research report on Wednesday, March 20th. They set a neutral rating on the stock. Finally, Gabelli cut Zoetis from a buy rating to a hold rating and set a $108.00 price objective on the stock. in a research report on Thursday, May 2nd. They noted that the move was a valuation call. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Zoetis has a consensus rating of Buy and an average target price of $105.00.

Zoetis stock opened at $110.16 on Tuesday. The stock has a market cap of $52.68 billion, a price-to-earnings ratio of 35.19, a PEG ratio of 2.75 and a beta of 0.87. Zoetis has a 52-week low of $78.90 and a 52-week high of $111.66. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.09. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.45 billion. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The business’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.75 EPS. On average, sell-side analysts expect that Zoetis will post 3.48 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 19th will be given a dividend of $0.164 per share. The ex-dividend date is Thursday, July 18th. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.60%. Zoetis’s payout ratio is currently 21.09%.

In related news, insider Roman Trawicki sold 4,700 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $109.00, for a total value of $512,300.00. Following the transaction, the insider now directly owns 2,199 shares of the company’s stock, valued at approximately $239,691. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Heidi C. Chen sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $104.23, for a total value of $260,575.00. Following the completion of the transaction, the insider now directly owns 11,463 shares in the company, valued at $1,194,788.49. The disclosure for this sale can be found here. Over the last three months, insiders sold 76,716 shares of company stock worth $7,805,856. 0.29% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of ZTS. Fulcrum Equity Management bought a new position in shares of Zoetis during the 4th quarter valued at approximately $841,000. RPg Family Wealth Advisory LLC increased its position in shares of Zoetis by 24,302.0% during the 4th quarter. RPg Family Wealth Advisory LLC now owns 48,804 shares of the company’s stock valued at $4,175,000 after purchasing an additional 48,604 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Zoetis by 2.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,425,455 shares of the company’s stock valued at $121,929,000 after purchasing an additional 39,319 shares during the last quarter. Raymond James & Associates increased its position in shares of Zoetis by 5.9% during the 1st quarter. Raymond James & Associates now owns 862,600 shares of the company’s stock valued at $86,839,000 after purchasing an additional 48,065 shares during the last quarter. Finally, WealthPLAN Partners LLC increased its position in shares of Zoetis by 6.4% during the 4th quarter. WealthPLAN Partners LLC now owns 3,894 shares of the company’s stock valued at $371,000 after purchasing an additional 233 shares during the last quarter. 90.30% of the stock is currently owned by institutional investors.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: Does the discount rate affect the economy?

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.